Advertisement

International Journal of Clinical Pharmacy

, Volume 36, Issue 4, pp 684–692 | Cite as

Optimizing pharmacotherapy of systemic lupus erythematosus: the pharmacist role

  • Maryam Al HussainiEmail author
  • Emad I. Hammouda
  • Ahmed E. Hammouda
Review Article

Abstract

Background Systemic lupus erythematosus (SLE) is a systemic autoimmune disease that can affect any part of the body. The management of the disease includes nonpharmacotherapy and pharmacotherapy. Aim of the review To provide an up-to-date review of the etiology, epidemiology, clinical features, diagnostic findings, and treatment options for SLE. Methods Data source: A PubMed search of English language journals using a combination of words—elderly, SLE, late onset SLE, etiology, screening, diagnosis, or treatment to identify original studies, guidelines, and reviews on SLE, SLE, late onset SLE published between 2000 and present. Overall, original studies, clinical reviews, references, and guidelines were obtained and evaluated on their clinical relevance. The literature included guidelines and considerations for the etiology, diagnosis, screening, and management of SLE, late onset SLE. Results SLE is a chronic autoimmune disorder, the exact etiology of which is unknown. SLE predominately affects younger women; however, it is reported to occur in up to 20 % of patients 50 years or older. In patients with SLE, nearly every system in the body is affected with varying degrees of severity ranging from subclinical to fatal. The hallmark feature of SLE is the production of autoantibodies directed primarily against nuclear antigens, but also against cytoplasmic components of cells. Conclusion The diagnosis of SLE is based on criteria set by the American College of Rheumatology. Management is individualized and depends on presenting symptoms and reducing the likelihood of permanent damage to organs and tissues.

Keywords

Elderly Geriatrics Late onset systemic lupus erythematosus Systemic lupus erythematosus Treatment 

Abbreviations

ALT

Alanine transaminase

ACR

American College of Rheumatology

ACEIs

Angiotensin converting enzyme inhibitors

Anti-DNA

Anti-deoxyribonucleic acid

Anti-dsDNA

Anti-doublestranded deoxyribonucleic acid

Anti-La/SS-B

Anti-La Sjorgren syndrome type B

Anti-Ro/SS-B

Anti-Ro/Sjorgren syndrome type B

ANA

Antinuclear antibodies

Anti-RNP

Anti ribonucleoprotein

Anti-Sm

Anti-Smith antibodies

AST

Aspartate transaminase

CBC

Complete blood count

COX-1

Cyclooxygenase-1

COX-2

Cyclooxygenase-2

EULAR

European league against rheumatism

MTX

Methotrexate

NSAIDs

Non-steroidal anti-inflammatory drugs

SLE

Systemic lupus erythematosus

Notes

Conflicts of interest

All authors stated that there is no conflict of interest in this study.

References

  1. 1.
    Agmon-Levin N, Blank M, Paz Z, Shoenfeld Y. Molecular mimicry in systemic lupus erythematosus. Lupus. 2009;18:1181–5.PubMedCrossRefGoogle Scholar
  2. 2.
    D’Cruz D, Khamashta M, Hughes G. Systemic lupus erythematosus. Lancet. 2007;369:587–96.PubMedCrossRefGoogle Scholar
  3. 3.
    Porth C, Matfin G. Pathophysiology: concepts of altered health states. 8th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2009.Google Scholar
  4. 4.
    Boltzer JW. Systemic lupus erythematosus. I. Historical aspects. MD State Med J. 1983;32:439–41.Google Scholar
  5. 5.
    Schur PH, Gladman DD. Overview of the clinical manifestations of systemic lupus erythematosus in adults. In: Basow DS, editor. Uptodate. MA: Waltham; 2012.Google Scholar
  6. 6.
    Alarcon-Riquelme ME. The genetics of systemic lupus erythematosus. J Autoimmun. 2005;25:46–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Bernknopf A, Rowley K, Bailey T. A review of systemic lupus erythematosus and current treatment options. Formulary. 2011;46:178–94.Google Scholar
  8. 8.
    Soldevilla H, Briones S, Navarra S. Systemic lupus erythematosus following HPV immunization or infection. Lupus. 2012;21:158–61.PubMedCrossRefGoogle Scholar
  9. 9.
    Bilj M, Reefman E, Horst G, Limburg PC, Kallenberg CG. Reduced uptake of apoptotic cells by macrophages in systemic lupus erythematosus: correlates with decreased serum levels of complement. Ann Rheum Dis. 2006;65:57–63.CrossRefGoogle Scholar
  10. 10.
    Dorner T, Jacobi A, Lee J, Lipsky PE. Abnormalities of B cell subsets in patients with systemic lupus erythematosus. J Immunol Methods. 2011;363:187–97.PubMedCrossRefGoogle Scholar
  11. 11.
    Jonsen A, Bengtsson A, Nived O, Truedsson L, Sturfelt G. Gene–environment interactions in the aetiology of systemic lupus erythematosus. Autoimmunity. 2007;40:613–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Tsokos G. Mechanisms of disease systemic lupus erythematosus. N Engl J Med. 2011;365:2110–21.PubMedCrossRefGoogle Scholar
  13. 13.
    Sebastiani GD, Galeazzei M. Infection–genetics relationship in systemic lupus erythematosus. Lupus. 2009;18:1169–75.PubMedCrossRefGoogle Scholar
  14. 14.
    Yildirim-Toruner C, Diamond B. Current and novel therapeutics in treatment of SLE. J Allergy Clin Immunol. 2011;127:303–14.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Zandmann-Goddard G, Solomon M, Rosman Z, Peeva E, Shonfeld Y. Environment and lupus related diseases. Lupus. 2012;21:241–50.CrossRefGoogle Scholar
  16. 16.
    Slawsky K, Fernandes A, Fusfeld L, Manzi S, Goss TF. A structured literature review of the direct costs of adult systemic lupus erythematosus in the US. Arthritis Care Res. 2011;63:1224–32.CrossRefGoogle Scholar
  17. 17.
    Arnaud L, Mathian A, Boddaert J, Amoura Z. Late-onset systemic lupus erythematosus. Drugs Aging. 2012;3:181–9.CrossRefGoogle Scholar
  18. 18.
    Vedove CD, Del Giglio M, Schena D, Gerolomoni G. Drug-induced lupus erythematosus. Arch Dermatol Res. 2009;301:99–105.PubMedCrossRefGoogle Scholar
  19. 19.
    Vasoo S. Drug induced lupus: an update. Lupus. 2006;15:757–61.PubMedCrossRefGoogle Scholar
  20. 20.
    Marzano A, Vezzoli P, Crosti C. Drug-induced lupus: an update on its dermatologic aspects. Lupus. 2009;18:935–40.PubMedCrossRefGoogle Scholar
  21. 21.
    Pons-Estel GJ, Alarcon GS, Cooper G. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum. 2010;39:257. doi: 10.1016/j.semarthrit.2008.10.007.PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Font J, Pallares L, Cervera R, Lopez-Soto A, Navarro M, Bosch X, Ingelmo M. Systemic lupus erythematosus in the elderly: clinical and immunological characteristics. Ann Rheum Dis. 1991;50:702–5.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Doria A, Iaccarino L, Ghirardello A. Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med. 2006;119:700–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Merrill M, Shulman LE. Determination of prognosis in chronic disease illustrated by systemic lupus erythematosus. J Chronic Dis. 1955;1:12–32.CrossRefGoogle Scholar
  25. 25.
    Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus. Results from a single centre. II. Predictor variables for mortality. J Rheumatol. 1995;22:1265–70.PubMedGoogle Scholar
  26. 26.
    Urowitz MB, Gladman DD, Tom BD, Ibanez D, Farewell VT. Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus. J Rheumatol. 2008;11:2152–8.CrossRefGoogle Scholar
  27. 27.
    Lazaro D. Elderly-onset systemic lupus erythematosus prevalence, clinical course and treatment. Drugs Aging. 2007;24:701–15.PubMedCrossRefGoogle Scholar
  28. 28.
    McPhee SJ, Papadakis MA. Current medical diagnosis and treatment. 48th ed. NewYork: McGraw-Hill; 2009.Google Scholar
  29. 29.
    Lalani S, Pope J, de Leon F, Peschken C. Clinical features and prognosis of late-onset systemic lupus erythematosus: results from the 1000 faces of lupus study. J Rheumatol. 2010;37:38–44.PubMedCrossRefGoogle Scholar
  30. 30.
    Gordon C, Jayne D, Pusey C, Adu D, Amoura Z, Aringer M, et al. European consensus statement on the terminology used in the management of lupus glomerulonephritis. Lupus. 2009;18:257–63.PubMedCrossRefGoogle Scholar
  31. 31.
    Bultink I. Osteoporosis and fractures in systemic lupus erythematosus. Arthritis Care Res. 2012;64:2–8.CrossRefGoogle Scholar
  32. 32.
    Bourré-Tessier J, Huynh T, Clarke A, Bernatsky S, Joseph L, Belisle P, et al. Features associated with cardiac abnormalities in systemic lupus erythematosus. Lupus. 2011;20:1518–25.PubMedCrossRefGoogle Scholar
  33. 33.
    El-Magadmi M, Bodill H, Ahmad Y, Durrington PN, Mackness M, Walker M, et al. Systemic lupus erythematosus an independent risk factor for endothelial dysfunction in women. Circulation. 2004;110:399–404.PubMedCrossRefGoogle Scholar
  34. 34.
    Adhikari T, Piatti A, Luggen M. Cognitive dysfunction in SLE: development of a screening tool. Lupus. 2011;20:1142–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Auerbach C, Beckerman N. What social workers in health care should know about lupus: a structural equation model. Health Soc Work. 2011;36:269–78.PubMedCrossRefGoogle Scholar
  36. 36.
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271–7.PubMedCrossRefGoogle Scholar
  37. 37.
    Smith E, Shmerling R. The American College of Rheumatology criteria for the classification of systemic lupus erythematosus: strengths, weaknesses, and opportunities for improvement. Lupus. 1999;8:586–95.PubMedCrossRefGoogle Scholar
  38. 38.
    Egner W. The use of laboratory tests in the diagnosis of SLE. J Clin Pathol. 2000;53:424–32.PubMedCentralPubMedCrossRefGoogle Scholar
  39. 39.
    Hull C. Systemic lupus erythematosus: a clinical review. Clin Rev. 2010;20:18–23.Google Scholar
  40. 40.
    Kalunian K, Merrill JT. New directions in the treatment of systemic lupus erythematosus. Curr Med Res Opin. 2009;6:1501–14.CrossRefGoogle Scholar
  41. 41.
    Common symptoms of lupus. Lupus Foundation of America 2012. http://www.lupus.org/webmodules/webarticlesnet/templates/new_learndiagnosing.aspx?articleid=2241&zoneid=524. Accessed 9 May 2012.
  42. 42.
    Ginzler E. Systemic lupus erythematosus (Lupus), American College of Rheumatology Patient Fact Sheet, 2012. http://www.rheumatology.org/practice/clinical/patients/diseases_and_conditions/lupus.asp. Updated Feb 2013.
  43. 43.
    Gladman DD, Urowitz MB, Esdaile JM, Hahn H, Kippel J, Lahita R, et al. Guidelines for referral and management of systemic lupus erythematosus in adults. Arthritis Rheum. 1999;9:1785–96.Google Scholar
  44. 44.
    Bertsias G, Loannidis JP, Boletis J, Bombardieri S, Cervera R, Dostal C, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics. Ann Rheum Dis. 2008;67:195–205.PubMedCrossRefGoogle Scholar
  45. 45.
    Amissah-Arthur MB, Gordon C. Contemporary treatment of systemic lupus erythematosus: an update for clinicians. Ther Adv Chronic Dis. 2010;1:163–75.PubMedCentralPubMedCrossRefGoogle Scholar
  46. 46.
    The Medical Letter Volume 10 (Issue15) March 2012.Google Scholar
  47. 47.
    The Medical Letter Volume 53 (Issue 1366) June 2011.Google Scholar
  48. 48.
    Mycophenolatemofetil capsules and tablets. Pennington, NJ: Zydus Pharmaceuticals USA,Inc; 2011 April.Google Scholar
  49. 49.
    Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systemic review. Ann Rheum Dis. 2010;69:20–8.PubMedCrossRefGoogle Scholar
  50. 50.
    Mazzoni D, Cicognani E. Social support and health in patients with systemic lupus erythematosus: a literature review. Lupus. 2011;20:1117–25.PubMedCrossRefGoogle Scholar
  51. 51.
    Sostres C, Gargallo CJ, Arroyo MT. Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res Clin Gastroenterol. 2010;24:121–32.PubMedCrossRefGoogle Scholar
  52. 52.
    Lander SA, Wallace DJ, Weisman MH. Celecoxib for systemic lupus erythematosus: case series and literature review of the use of NSAIDs in SLE. Lupus. 2002;11:340–7.PubMedCrossRefGoogle Scholar
  53. 53.
    Horizon AA, Wallace DJ. Risk: benefit ratio of nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus. Expert Opin Drug Saf. 2004;3:273–8.PubMedCrossRefGoogle Scholar
  54. 54.
    Scheiman JM, Hindley CES. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events. Clin Ther. 2010;32:667–77.PubMedCrossRefGoogle Scholar
  55. 55.
    Tam LS, Gladman DD, Hallett DC, Rahman P, Urowitz MB. Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. J Rheumatol. 2000;9:2142–5.Google Scholar
  56. 56.
    Kuznik A, Bencina M, Svajger U, Jeras M, Rozman B, Jerala R. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol. 2011;186:1–11.CrossRefGoogle Scholar
  57. 57.
    Fortin PR, Abrahamowicz M, Ferland D, Lacaille D, Smith CD, Zummer M, et al. Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double blind, randomized, placebo-controlled trial. Arthritis Rheum. 2008;59:1796–804.PubMedCrossRefGoogle Scholar
  58. 58.
    Islam N, Hossain M, Haq SA, Alam MN, Peter M, Klooster T, et al. Efficacy and safety of methotrexate in articular and cutaneous manifestations of systemic lupus erythematosus. Int J Rheum Dis. 2012;15:62–8.PubMedCrossRefGoogle Scholar
  59. 59.
    Shum K, Askanase A. Treatment for lupus nephritis. Curr Rheumatol Rep. 2011;13:283–90.PubMedCrossRefGoogle Scholar
  60. 60.
    Popescu A, Kao AH. Neuropsychiatric systemic lupus. Erythematosus. Curr Neuropharmacol. 2011;9:449–57.PubMedCentralPubMedCrossRefGoogle Scholar
  61. 61.
    Kamanamool N, McEvoy M, Attia J, Ingsathit A, Ngamjanyaporn P, Thakkinstian A. Efficacy and adverse events of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis. Medicine. 2010;89:227–35.PubMedCrossRefGoogle Scholar
  62. 62.
    Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011;365:1886–95.PubMedCrossRefGoogle Scholar
  63. 63.
    Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al. Efficacy and safety of Belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:721–31.PubMedCrossRefGoogle Scholar
  64. 64.
    Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzova D, et al. A phase III, randomized, placebo-controlled study of Belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;12:3918–30.CrossRefGoogle Scholar
  65. 65.
    Day RO, Graham GG, Champion GD, Lee E. Anti-rheumatic drug interactions. Clin Rheum Dis. 1984;2:251–75.Google Scholar
  66. 66.
    Johnson AG, Seideman P, Day RO. Adverse drug interactions with nonsteroidal anti-inflammatory drugs (NSAIDs), recognition, management and avoidance. Drug Saf. 1993;8:99–127.PubMedCrossRefGoogle Scholar
  67. 67.
    Kamen DL. Vitamin D in lupus: new kid on the block. Bull NYU Hosp Jt Dis. 2010;68:218.PubMedGoogle Scholar
  68. 68.
    Toloza S, Cole D, Gladman DD, Ibanez D, Urowitz MB. Vitamin D insufficiency in a large female SLE cohort. Lupus. 2010;19:13–9.PubMedCrossRefGoogle Scholar
  69. 69.
    Grossman JM, Gordon R, Ranganath VK, Deal C, Chen W, Curtis JR, et al. American college of rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res. 2010;62:1515–26.CrossRefGoogle Scholar
  70. 70.
    Ortiz Z, Shea B, Suarez-Almazor ME, Moher D, Wells GA, Tugwell P. Folic acid and follinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. Cochrane Database of Systematic Reviews 1999, Issue 4. Art. No.: CD000951.Google Scholar

Copyright information

© Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie 2014

Authors and Affiliations

  • Maryam Al Hussaini
    • 1
    Email author
  • Emad I. Hammouda
    • 2
  • Ahmed E. Hammouda
    • 3
  1. 1.Department of Pharmaceutical Sciences, College of Health SciencesPublic Authority for Applied Education and Training (PAAET)KuwaitKuwait
  2. 2.Pharmacy DepartmentTawam Hospital in Affiliation with John Hopkins MedicineAl AinUnited Arab Emirates
  3. 3.Faculty of PharmacyGerman University of CairoCairoEgypt

Personalised recommendations